Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival
Checkpoint inhibitors have revolutionized the treatment of patients with metastasized melanoma. However, it remains unclear when to stop treatment. We retrospectively analyzed 45 patients (median age 64 years; 58% male) with metastasized melanoma from 3 cancer centers that received checkpoint inhibi...
Main Authors: | Timo E. Schank, Andrea Forschner, Michael Max Sachse, Antonia Dimitrakopoulou-Strauss, Christos Sachpekidis, Albrecht Stenzinger, Anna-Lena Volckmar, Alexander Enk, Jessica C. Hassel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2616 |
Similar Items
-
Quantitative, Dynamic <sup>18</sup>F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report
by: Christos Sachpekidis, et al.
Published: (2021-04-01) -
Quantitative Dynamic <sup>18</sup>F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
by: Christos Sachpekidis, et al.
Published: (2021-03-01) -
Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic <sup>18</sup>F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group
by: Christos Sachpekidis, et al.
Published: (2019-06-01) -
Positron Emission Tomography in Merkel Cell Carcinoma
by: Christos Sachpekidis, et al.
Published: (2020-10-01) -
PET-FDG: Impetus
by: Cristina Nanni
Published: (2020-04-01)